 Mortality reductions demonstrated across multiple patient groups Additional efficacy signals recorded in a broad range of mild to severe ARDS patients Company to focus on critically ill population for Phase 3 TORONTO, ON ACCESSWIRE October 19, 2021 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced additional results from the Phase 2 part of an ongoing Phase 23 clinical study evaluating the companys monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients. The Phase 2 data were preemptively unblinded last month by the studys Data and Safety Monitoring Board DSMB due to a clinically important efficacy signal detected among the most critically ill patients. 